Financial Daily from THE HINDU group of publications
Wednesday, May 26, 2004

Cross Currency

Group Sites

Corporate - Announcements

Dr Reddy's gets USFDA nod for Fluconazole

C.R. Sukumar

Hyderabad , May 25

IN a major boost to its patent challenging strategy, Dr Reddy's Laboratories Ltd, the Hyderabad-based global pharmaceutical major, has obtained the tentative approval of the United States Food and Drugs Administration (USFDA) for the abbreviated new drug application filed on Fluconazole, indicated for the treatment of fungal infection.

Currently, Pfizer holds patent on the product under the brand `Diflucan', which had a market of $447 million during the last year. The drug is scheduled to go off patent on July 29 this year.

Confirming the receipt of the tentative approval for Fluconazole, Dr Reddy's sources told Business Line that the company would initiate steps to launch the product in the US market after the expiry of patents once it receives the final approval from the USFDA.

"The USFDA's tentative approval is the first step toward sale of the drug in the US market. We need to get final approval from the regulator to launch the drug once the patent expires," sources said.

More Stories on : Announcements | Pharmaceuticals | Regulatory Bodies & Rulings

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Avesthagen gets Rs 2.75-cr CSIR grant

Murugappa Group receives Parrys sale consideration
Dr Reddy's gets USFDA nod for Fluconazole
GM India to launch special edition of Corsa
Apollo Health to open clinic in Doha
Aurobindo Pharma results on June 2
Sakthi Sugars pref allotment to FIIs
Matrix Labs allots shares to foreign funds
LIC MF third suitor for GIC Mutual
SRF to acquire arm's polyester film business
Hincol bitumen plant at Vizag
`We are planning to unveil 25 new products in next 2 years'
Consolidation to place Amtek Auto in top gear

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line